Six Weeks of Mupirocin and a Patient Who Refuses Debridement

This is not a spreading infection. It is critical colonization/biofilm - and the distinction drives everything else.

Findings that point to biofilm rather than infection:

• Slough re-forming within 48 hours of cleansing is a hallmark of biofilm: the community regrows quickly after mechanical disruption.
• Foul odor and moderate drainage reflect bacterial load and anaerobes, not invasion.
• Erythematous, macerated periwound is consistent with moisture and exudate, not cellulitis.
• Induration confined to under 2 cm, no lymphangitis, no systemic signs (WBC 7.2, afebrile) - the criteria for clinical infection are not met.

Therefore: no systemic antibiotics. Starting them would treat a surface biofilm with a systemic drug, select for resistance, and skip the actual intervention - repeated mechanical disruption of the biofilm plus moisture control.

Caveat to state explicitly: reassess at each visit. If induration spreads, erythema advances, new pain or tenderness develops, drainage becomes purulent, or she becomes febrile or systemically unwell, the classification changes and antibiotics plus possible culture are warranted. With an ABI of 1.02, vascular status is adequate, which lowers the threshold for concern but does not manufacture an infection that is not there. The 14-month duration tells you the wound has never been properly prepared, not that it has been under-treated with antibiotics.

Reframe: debridement is a category, not a procedure. The goal is to remove slough and disrupt biofilm; sharp technique is only one route to it.

Ranked options for this wound

1. Address the pain first, then revisit sharp. Her refusal is driven by an experience, not a preference. Premedicate 30–60 minutes before the procedure with an agent matched to onset, use a topical anesthetic, work in short sessions, and give her control (a stop signal, a set time limit). Many refusals dissolve once the pain is genuinely controlled.
2. Conservative sharp debridement in small serial sessions by a qualified clinician - a few minutes per visit rather than one long, traumatic encounter.
3. Enzymatic debridement (collagenase) - selective for necrotic tissue, appropriate for a patient who will not tolerate sharp, and pairs well with moisture balance.
4. Autolytic debridement - a hydrogel or semi-occlusive dressing to soften slough and let the body do the work; slower, but well tolerated and painless.
5. Mechanical/adjunctive - monofilament pad or pad-and-solution cleansing at each dressing change to disrupt biofilm, with gentle technique that does not strip new tissue.

Pair with moisture management. The macerated periwound needs a dressing that handles moderate drainage and protects the surrounding skin - the slough will keep returning if the wound stays wet. Keep the 40 mmHg compression, since ABI 1.02 supports it and venous hypertension is the engine of this ulcer.

Set the expectation: if no progress over a defined interval (e.g., 4 weeks of consistent debridement plus moisture control), escalate for a different approach, not for antibiotics.

The order is inappropriate on three counts.

1. Wrong indication. Mupirocin is indicated for impetigo and similar superficial Staphylococcus aureus skin infections. It is not a treatment for chronic wound biofilm, and slough in a venous ulcer is a polymicrobial biofilm, not a staphylococcal impetigo.
2. Wrong duration. Six weeks of a topical antibiotic in a chronic wound is a resistance-selection engine. Prolonged use also drives mupirocin resistance in S. aureus, which matters well beyond this patient.
3. It substituted for debridement. Six weeks of the wrong product with an 80% slough bed means the actual barrier to healing was never addressed. That is the stewardship lesson: an ineffective topical is not a neutral choice, it is a delay.

Recommend instead

• Discontinue mupirocin.
• A time-limited topical antiseptic challenge with a defined endpoint, chosen for the wound: cadexomer iodine (check for iodine allergy and thyroid history) or a PHMB-based product, used for roughly 2 weeks with a planned reassessment. Antiseptics are for reducing bioburden over a defined period, not indefinite use.
• Debridement plus moisture management as the primary therapy - see the previous plan; the antiseptic supports that work rather than replacing it.
• Culture only if clinical infection develops. Swab cultures of a colonized chronic ulcer mostly grow colonizers and drive unnecessary antibiotic use.

Document the rationale and the review date so the stewardship decision is visible and gets re-evaluated rather than drifting into another six weeks.